NCT07252531招募中不适用
European Investigation of the BrioVAD Left Ventricular Assist System for the Treatment of Refractory Left Ventricular Heart Failure
BrioHealth BV2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年6月1日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Survival rate at 6 months
研究概览
简要总结
This clinical investigation evaluates the safety and clinical performance of the BrioVAD Left Ventricular Assist System in patients with advanced, refractory left ventricular heart failure who require mechanical circulatory support.
详细描述
This clinical investigation is conducted to assess the clinical performance and safety of the BrioVAD Left Ventricular Assist System (BrioVAD System) when used for mechanical circulatory support in patients with advanced, refractory left ventricular heart failure.
The BrioVAD System is a fully magnetically levitated, centrifugal-flow left ventricular assist device (LVAD) intended to provide short-term and long-term mechanical circulatory support (MCS) in patients with advanced, refractory heart failure who remain symptomatic despite optimal medical and device therapy. The BrioVAD System is intended for use both inside and outside the hospital environment.
This investigation is designed as a prospective, multi-centre, single-arm, non-inferiority clinical investigation. The performance of the BrioVAD System will be evaluated against a pre-defined Objective Performance Goal (OPG) based on contemporary LVAD clinical outcomes.
The primary objective is to demonstrate that the BrioVAD System provides non-inferior clinical benefit, as measured by survival free from device replacement/removal due to device malfunction at 6 months post-implant, compared with the OPG.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is ≥ 18 years of age.
- •Patient has a body surface area (BSA) ≥ 1.2 m
- •Patient is classified as NYHA Class IV with advanced heart failure refractory to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.
- •Patient has a left ventricular ejection fraction (LVEF) ≤ 25% or LVEF < 30% on inotropes or intra-aortic balloon pump (IABP).
- •Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters/min/m2, while not on inotropes, and also meets one of the following criteria:
- •Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or
- •Has advanced heart failure for at least 14 days and is dependent on an IABP for at least seven days.
- •Patient has provided voluntary and informed consent.
- •Females of childbearing age agree to use adequate contraception and have a negative pregnancy test.
排除标准
- •Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis/senile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and/or pericardial disease.
- •Patient had a myocardial infarction within seven days before study enrollment.
- •Patient had cardiothoracic surgery within 30 days before implant.
- •Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.
- •Patient has contraindications to warfarin anticoagulation.
- •Patient has known hypo- or hypercoagulable state [e.g., disseminated intravascular coagulation (DIC)], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.
- •Patient is on durable MCS (e.g., LVAD or RVAD).
- •Planned need for durable or temporary RVAD support concomitant with LVAD implant.
- •Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an IABP.
- •Patient is on any form of pre-implant temporary MCS with a serum lactate dehydrogenase greater than 2.5 times the upper limits of normal or with plasma free hemoglobin > 40 g/dL.
- •Patient has a history of organ transplantation.
- •Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.
- •Patient has a platelet count < 50 k/µl.
- •Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter.
- •Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.
- •Patient has an uncontrolled systemic infection.
- •Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin >1000 ug/L.
- •Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:
- •Total bilirubin > 3.0 mg/dL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without biopsy confirmation.
- •International normalized ratio (INR) ≥ 2.0 or PTT > 2.5 times control that is not related to anticoagulation therapy.
- •Glomerular filtration rate (GFR) < 30 mL/ min/1.73 m2 or need for renal replacement therapy.
- •Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.
- •Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen or an FEV1/FVC < 0.7 and FEV1 < 40% predicted.
- •Mechanical ventilation for more than three days present at the time of study enrollment.
- •Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.
- •History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.
- •Symptomatic cerebrovascular disease and/or uncorrected carotid stenosis > 80%.
- •Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.
- •Pre-albumin < 15 mg/dL and/or albumin < 2.5 g/dL.
- •Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.
- •Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and/or insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.
- •Patient is participating in an interventional clinical trial that may impact or confound the results of the BrioVAD Trial.
研究组 & 干预措施
Treatment group
Experimental
干预措施: LVAD implantation (Device)
结局指标
主要结局
Survival rate at 6 months
时间窗: From enrollment to 6 months on device support
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility TrialCardiomyopathiesEnd-Stage Heart FailureNCT00490347Ventracor30
Unknown
3 期
VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal TrialCardiomyopathiesEnd-stage Heart FailureNCT00483197Ventracor140
Unknown
3 期
VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination TherapyCardiomyopathiesEnd-stage Heart FailureNCT00490321Ventracor225
已完成
4 期
Efficacy Study of LV Assist Device to Treat Patients With Cardiogenic Shock (ISAR-SHOCK)Shock, CardiogenicMyocardial InfarctionNCT00417378Deutsches Herzzentrum Muenchen26
撤回
1 期
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device SupportLeft Ventricular Assist DeviceNatriuretic PeptideHeart FailureNCT03091998Mayo Clinic